Efficacy
nocturnal back pain, pain
The percentage of patients who achieved the primary efficacy endpoint of ASAS40 response at week 14 (NRI-MI: 45%) continued to increase with continuous upadacitinib treatment through 52 weeks (NRI-MI: 66%; Fig. ASAS40 (The percentage of patients who achieved ASDAS LDA and ID generally followed a similar pattern, with continued improvements through week 52 for both the continuous upadacitinib group (NRI-MI: 57% and 26%, respectively) and the placebo to upadacitinib group (NRI-MI: 55% and 25%, respectively; Fig. Improvements observed at week 14 were maintained in the continuous upadacitinib group through week 52, and similar improvements were achieved in the placebo to upadacitinib group at week 52, for change from baseline in total back pain, nocturnal back pain, and function, respectively (Fig. Mean change in total back pain (In the subgroups of patients who had discontinued prior bDMARD treatment due to lack of efficacy versus intolerance, as well as the subgroups of patients who had prior treatment with TNFis versus IL-17is, similar response rates were observed for ASAS40 and other endpoints at week 52 in both the continuous upadacitinib and placebo to upadacitinib groups (Supplementary Tables 